Benchmark on Monday launched coverage of Dexcom with a Buy rating and a $77 price target, saying the medical technology company is positioned to lift margins meaningfully through platform migration and lower-cost manufacturing. The price objective represents roughly 30% upside from the most recent closing price.
The analyst firm's thesis rests principally on Dexcom's G7 15 Day continuous glucose monitoring system. Dexcom made the G7 15 Day widely available in January 2026 following an April 2025 FDA clearance. The sensor extends wear time to 15 days and is noted in the coverage initiation for higher accuracy and reduced frequency of sensor changes for users.
As part of its product transition plan, Dexcom intends to discontinue the older G6 system on July 1 and move current G6 users to the G7 platform. Benchmark says that migrating the installed base onto G7 should accelerate production volume for the new sensor and enable cost reductions as manufacturing scales.
"Dexcom is poised for margin expansion over the next two years as it launches a new continuous glucose monitor sensor, the G7 15 Day system," analyst Bruce Jackson said. "The idea is to drive volume to the new platform while ramping up lower-cost manufacturing, leading to scale efficiencies and improved gross margins."
Dexcom has provided guidance for adjusted gross margins in 2026 of 63-64%, which Benchmark notes is about a 200 basis point improvement compared with 2025. The firm highlighted that a newly opened manufacturing facility in Ireland is expected to weigh on operating margins during the first three quarters of 2026 before becoming accretive as the site ramps up late in the year.
International markets are also part of the expected volume story. Benchmark pointed to expanded reimbursement coverage for insulin-using Type 2 diabetes patients in Germany, France, and the United Kingdom as a driver of growth; Dexcom reported international revenue growth of 26% in the first quarter of 2026.
Beyond those reimbursement expansions already underway, Benchmark flagged upside potential from additional reimbursement coverage for non-insulin-using Type 2 patients. The analyst noted Medicare in the United States as an example of a payer not currently reflected in the firm's estimates, implying further reimbursement developments could produce incremental benefit.
In sum, Benchmark's initiation emphasizes a sequence of product migration to G7, manufacturing scale and cost efficiency, and international reimbursement expansion as the key components supporting the Buy rating and $77 price target.
Note: This article reports the points and guidance as stated in the coverage initiation and company guidance; it does not add or interpret facts beyond those provided.